Latest news: Vaccines authorized or under evaluation by EMA

Plenty of news regarding COVID-19 vaccines this week.

Plenty of news regarding COVID-19 vaccines this week.
March 4, 2021

Plenty of news regarding COVID-19 vaccines this week: on the one hand, today EMA announced that the Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of Sputnik V (Gam-COVID-VAC) COVID-19 Vaccine. On the other hand, EMA also notified that the CHMP will hold an extraordinary meeting on the 11th of March in order to conclude the evaluation of the COVID-19 vaccine developed by Janssen-Cilag International N.V. If there is a positive outcome to this meeting, the evaluation process (which started with a rolling review on December 2020 and was followed by the conditional marketing authorisation evaluation on mid-February 2021) would be completed. If this vaccine is authorized, a total of 4 vaccines will be available on the European market, with three more on the way, already under EMA’s evaluation.

Asphalion is actively aiding in the development of new medicines to treat or prevent COVID-19. With each announcement of the authorization of new treatments and the hope they bring with them, we are sure that this development projects are worth each ounce of the invested effort.

For further information you can contact us at: info@asphalion.com

Search News & Events

  • Filter by category

Share

Related news and events

EVENT | 20th Biosimilar Medicines Conference by MFE

During these two interactive days, actors of the healthcare community alongside world experts in biosimilar medicines will gather and debate the evolving biosimilar medicines landscape and emerging trends. Discussion will focus on sharing good practices and setting collective aims to achieve the depth, breadth and speed of the use of biosimilar medicines as a lever to untap their transformative value.

BUSINESS CASE | Transparency policy 0070

Have a look at this Business Case where Asphalion provided a leading global pharmaceutical company with full regulatory support for the management of Policy 0070

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting